Skip to main content
Harsh R. Shah
( out of 90 reviews )

Harsh R. Shah, DO

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626
  • Languages Spoken: English, Hindi, Gujarati

    Harsh Shah DO is an Assistant Professor of Medicine in the Division of Hematology at the Huntsman Cancer Center, University of Utah.

    Dr. Shah’s clinical expertise is in treatment of various lymphomas, such as Hodgkin’s Lymphoma, T-cell Lymphomas, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, CLL, etc. He has a research interest in immunotherapy resistance pathways in treatment of Hodgkin Lymphomas, particularly the role of Tumor Associated Macrophages. He is also interested in outcomes research and novel educational strategies for medical students, residents, and fellows.

    He completed his internal medicine training at Indiana University in Indianapolis and hematology and oncology fellowship at Karmanos Cancer Institute/Wayne State University in Detroit, Michigan. He is certified in both hematology and oncology.

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 90 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    April 21, 2024
    HUNTSMAN CANCER CENTER

    not only is he an knowledgeable, medical practitioner, but he¿s kind, personable and assures me that he¿s interested in my well-being

    March 28, 2024
    HUNTSMAN CANCER CENTER

    Dr. Shah was great. He discussed my past medical history and followed up on the next steps.

    March 14, 2024
    HUNTSMAN CANCER CENTER

    I found Dr Shah to be very caring, understanding and professional. Dr Shah listened to me and put me at ease.

    March 09, 2024
    HUNTSMAN CANCER CENTER

    Doctor shah was amazing and treated me so good and helped me get better.

    January 28, 2024
    HUNTSMAN CANCER CENTER

    He answered all of our questions, and didn't rush us. We told him of our we questions about the drug we were taking and the costs and he had his pharmacist meet with us to help with getting the drug affordable.

    January 21, 2024
    HUNTSMAN CANCER CENTER

    I thank Dr Shah for treating me with respect and assuring me of the future.

    December 04, 2023
    HUNTSMAN CANCER CENTER

    Dr. Shah took me seriously and gave me the time and attention I needed. I felt like I was getting the best advice possible.

    November 09, 2023
    HUNTSMAN CANCER CENTER

    Good at explaining my results

    October 29, 2023
    HUNTSMAN CANCER CENTER

    The first time I met Dr. Shah I immediately knew I was in good hands and I had complete confidence in his abilities to provide me with the most effective treatment plan.

  • Languages Spoken: English, Hindi, Gujarati

    Harsh Shah DO is an Assistant Professor of Medicine in the Division of Hematology at the Huntsman Cancer Center, University of Utah.

    Dr. Shah’s clinical expertise is in treatment of various lymphomas, such as Hodgkin’s Lymphoma, T-cell Lymphomas, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, CLL, etc. He has a research interest in immunotherapy resistance pathways in treatment of Hodgkin Lymphomas, particularly the role of Tumor Associated Macrophages. He is also interested in outcomes research and novel educational strategies for medical students, residents, and fellows.

    He completed his internal medicine training at Indiana University in Indianapolis and hematology and oncology fellowship at Karmanos Cancer Institute/Wayne State University in Detroit, Michigan. He is certified in both hematology and oncology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology-Oncology - Karmanos Cancer Institute - Wayne State University Fellow
    Internal Medicine - Indiana University School of Medicine Resident
    Professional Medical Osteopathic Medicine - Kirksville College of Osteopathic Medicine - AT Still University of Health Sciences D.O.
    Biomedical Engineering - University of Michigan M.S.E.
    Undergraduate Biomedical Engineering - University of Michigan B.S.E.

    Selected Publications

    Journal Article

    1. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. (Read full article)
    2. Desai SH, Spinner MA, Evens AM, Sykorova A, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Chang C, Michalka J, Ansell SM, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Wagner-Johnston N, Arai S, Nowakowski GS, Mocikova H, Jagadeesh D, Blum KA, Diefenbach C, Iyengar S, Rappazzo KC, Baidoun F, Choi Y, Prochazka V, Advani RH, Micallef I (2023). Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Adv, 7(23), 7295-7303. (Read full article)
    3. Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open, 6(6), e2316642. (Read full article)
    4. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
    5. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Ramakrishnan Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL (2023). Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma. Clin Cancer Res. (Read full article)
    6. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. (Read full article)
    7. Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, Dorritie K, Azzi J, Kenkre VP, Arai S, Chang C, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah H, Murphy J, Ansell S, Jagadish D, Orellana-Noia V, Diefenbach C, Iyenger S, Rappazzo KC, Mishra R, Choi Y, Nowakowski GS, Advani RH, Micallef IN (2023). Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. (Read full article)
    8. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 1-8. (Read full article)
    9. Shah H, Jang H, Kim S, Halwani AS (2022). A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race. Br J Haematol. (Read full article)
    10. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. (Read full article)
    11. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2022). Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. Clin Cancer Res, 28(15), 3242-3247. (Read full article)
    12. Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A (2021). Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents. Leuk Lymphoma, 63(4), 813-820. (Read full article)
    13. Shah HR, Stephens DM (2021). Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program, 2021(1), 68-75. (Read full article)
    14. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 139, 413-423. (Read full article)
    15. Shah H, Stephens D, Seymour J, Maddocks K (2021). Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. Am Soc Clin Oncol Educ Book, 41, 1-18. (Read full article)
    16. Vaishampayan U, Shah H, Asad MF, Shi D, Dickow B, Suisham S, Domina J, Cher ML, Samantray J, Aoun HD (2020). Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. J Kidney Cancer VHL, 7(4), 1-7. (Read full article)
    17. Shah H, Kim S, Singh P, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Deol A (2019). Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts. Am J Hematol, 95(2), 198-204. (Read full article)
    18. Shah H, Vaishampayan U (2018). Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. Target Oncol, 13(6), 679-689. (Read full article)
    19. Shah H, Bradford C, Sayar H (2015). Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis. Case Rep Hematol, 2015, 826894. (Read full article)

    Review

    1. Salem AE, Shah HR, Covington MF, Koppula BR, Fine GC, Wiggins RH, Hoffman JM, Morton KA (2022). PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies. [Review]. Cancers (Basel), 14(23). (Read full article)

    Case Report

    1. Shah H, McPherson K, Mansour A, Ramirez-Santrich C, Nassiri M, Shahda S (2016). Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia. Clin Colorectal Cancer, 15(4), e235-e239. (Read full article)

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. (Read full article)
    2. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. [Letter to the editor]. J Hematol Oncol, 16(1), 111. (Read full article)
    3. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. (Read full article)
    4. Shah H, Kim S, Klimecki S, Charlson K, Uberti J, Schiffer CA, Fiala MA, Seymour E (2022). Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center. [Letter to the editor]. Bone Marrow Transplant, 57, 1213-1215. (Read full article)
  • News & Podcasts